TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05487794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Cypionate 100 MG/ML
Description: Testosterone is also responsible for increasing hematocrit by stimulating erythropoiesis (Velho et al., 2017). In cisgender men, who are hypogonadal and do not adequately produce testosterone, treatment with the use of testosterone is associated with stimulation of erythropoiesis, which can potentially increase blood viscosity, resulting in secondary erythrocytosis (Hajjar et al., 1997).
Study: NCT05568589

Intervention type: OTHER
Intervention: Preoperative Interpectoral - Pectoserratus Plane Block
Description: Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.
Study: NCT05905744

Intervention type: DIAGNOSTIC_TEST
Intervention: cholangioscopy
Description: cholangioscopy examination and forceps biopsy, followed by brush biopsy from ERCP
Study: NCT05887583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Rising New York Road Runners program
Description: The Rising New York Road Runners program provides lesson plans covering fundamental movement skills that are intended to build competence, confidence, and motivation to be physically activity. Family engagement materials (emails, text messages, videos, social media) complement school materials to communicate what children are learning at school related to physical activity and what activities families can do at home together to reinforce these concepts.
Study: NCT04707859

Intervention type: DIAGNOSTIC_TEST
Intervention: Head to head comparison: Rubidium vs 15O-water PET
Description: Head to head comparison with invasive FFR as reference. Adjustment for abnormal microcirculation
Study: NCT05874167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW6013
Description: Drug: DW6013 Single oral administration of DW6013 after an overnight fast~Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin after an overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW6013
Description: Drug: DW6013 Single oral administration of DW6013 after an overnight fast~Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin after an overnight fast
Study: NCT06276738

Intervention type: DIAGNOSTIC_TEST
Intervention: LINFU® (Low Intensity Non-Focused Ultrasound excitation of the pancreas)
Description: Patients will undergo low intensity non-focused ultrasound excitation of the pancreas for a total of 15 minutes. A contrast agent will be administered IV at five minute intervals. The patient will then receive a dose of secretin and the the patient's pancreatic juice will then be collected for a total of 15 minutes.
Study: NCT06341790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: jowar based products
Description: jowar based products like jowar flakes, jowar aata, jowar vermicelli is given to the intervention group
Study: NCT05568589

Intervention type: OTHER
Intervention: Intraoperative Interpectoral - Pectoserratus Plane Block
Description: Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.

Intervention type: OTHER
Intervention: Non Block
Description: Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.
Study: NCT04317755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AdhaFULL body image comics
Description: The comics were co-created with the expertise of four stakeholders: the investigators, UNICEF, BBC Media Action, and the Dove Self-Esteem Project. There are six different comics, which target issues relating to gender stereotypes and appearance concerns amongst adolescents in rural India. Based on 'Dove Confident Me', each comic tells a story which targets a specific established risk factor for body dissatisfaction. Specifically, they focus on gender prejudice (Comic 1), societal appearance ideals (Comic 2), media literacy (Comic 3), appearance comparisons (Comic 4), appearance-related conversations and teasing (Comic 5), and promoting 'body activism' (Comic 6). In each session, students will read the respective comic as a class. At the end of each comic, the teacher will facilitate one or two activities with the students based on the key learnings from the comics. These activities will encourage students to think critically about what they have read and consolidate their learning.
Study: NCT06325514

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligence based program
Description: the AI based program is based on image analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligence based program
Description: the AI based program is based on image analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligence based program
Description: the AI based program is based on image analysis
Study: NCT04863963

Intervention type: PROCEDURE
Intervention: Milligan Morgan
Description: Surgical intervention used in case of Goligher's grade III hemorrhoidal disease
Study: NCT06111989

Intervention type: BEHAVIORAL
Intervention: Neuropsychological testing
Description: The neuropsychological assessment will involve paper and pencil tests, computerized tests (such as reaction time measurements) and a driving simulator.

Intervention type: BEHAVIORAL
Intervention: On road test
Description: The driving instructor will guide the participant on a standard route, and will evaluate the performance using standard criteria that will focus mainly on traffic safety.
Study: NCT05614856

Intervention type: DEVICE
Intervention: EVAR off-label use
Description: Normally a femoral access was used, although a brachial approach can be useful for crossing total occlusions. For TASC B and C lesions, predilatation of the iliac lesions is advisable, while for TASC D it is mandatory. In case of total aortic occlusions, the procedure demands that recanalization of the distal aorta occurs as close as possible to the bifurcation.. The key technique is to recanalize from one common iliac artery into the opposing snaring the wire to create a femoral-femoral crossover. The femoral-femoral wire is then replaced with a MPA catheter; the SurePass wire attached to the contralateral limb is then passed through the catheter. The sheath can be placed within 5 cm of the aortic bifurcation, and the AFX can be delivered through the common iliac and aortic occlusion. Predilatation were performed with bilateral 6-8 mm x 150 mm balloons and or progressive dilatators.
Study: NCT04940962

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sampling of adipose tissue
Description: Removal of less than 1 cm3 of adipose tissue during visceral surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sampling of adipose tissue
Description: Removal of less than 1 cm3 of adipose tissue during visceral surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sampling of adipose tissue
Description: Removal of less than 1 cm3 of adipose tissue during visceral surgery
Study: NCT05253105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB006
Description: Recombinant humanized, IgG4κ (immunoglobulin gamma 4, kappa) monoclonal antibody (mAb) that specifically binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB006
Description: Recombinant humanized, IgG4κ (immunoglobulin gamma 4, kappa) monoclonal antibody (mAb) that specifically binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB006
Description: Recombinant humanized, IgG4κ (immunoglobulin gamma 4, kappa) monoclonal antibody (mAb) that specifically binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB006
Description: Recombinant humanized, IgG4κ (immunoglobulin gamma 4, kappa) monoclonal antibody (mAb) that specifically binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB006
Description: Recombinant humanized, IgG4κ (immunoglobulin gamma 4, kappa) monoclonal antibody (mAb) that specifically binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB006
Description: Recombinant humanized, IgG4κ (immunoglobulin gamma 4, kappa) monoclonal antibody (mAb) that specifically binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)
Study: NCT05813223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Purinergic (P2X3) Receptor antagonist. Film-coated tablet taken orally.
Study: NCT06306872

Intervention type: DRUG
Group type: OTHER
Intervention: Sequence A ABSK-011
Description: Subjects in sequence A will receive 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) Oral administration of ABSK-011 old formulation at the first day of cycle 1 (C1D1), followed by a washout period of at least 4 days.Subjects will receive 200 mg(100 mg capsule \*2) Oral administration of ABSK-011 new formulation at the first day of cycle 2 (C2D1).
Study: NCT05448118

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Virtual POC Toxicology Test
Description: Providers and patients will use Saliva Toxicology test at the point of care during virtual care visits.
Study: NCT06322719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperangulated blade videolaryngoscope
Description: For patients assigned to the Hyperangulated videolaryngoscope Group, the operator will use a Hyperangulated video laryngoscope on the first laryngoscopy attempt.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh blade videolaryngoscope
Description: For patients assigned to the Macintosh videolaryngoscope Group, the operator will use a Hyperangulated video laryngoscope on the first laryngoscopy attempt.
Study: NCT05253105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)
Study: NCT05492630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC73077 tablets
Description: Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study.
Study: NCT06306872

Intervention type: DRUG
Group type: OTHER
Intervention: Sequence B ABSK-011
Description: Subjects in sequence A will receive 200 mg(100 mg capsule \*2) Oral administration of ABSK-011 old formulation at the first day of cycle 1 (C1D1), followed by a washout period of at least 4 days.Subjects will receive 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) Oral administration of ABSK-011 new formulation at the first day of cycle 2 (C2D1).
Study: NCT05471713

Intervention type: OTHER
Intervention: Autonomic dysfunction
Description: Autonomic dysfunction
Study: NCT05492630

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC73077 placebo tablets
Description: Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study.
Study: NCT05792774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: The experimental intervention will consist of ultrasound-guided anesthetic blockade of the phrenic nerve at the laterocervical supraclavicular level with 1 ml of lidocaine without vasoconstrictor 2% to infiltrate the skin and 3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade, making the local anesthetic surround the nerve between the anterior scalene muscle and the sternocleidomastoid muscle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (physiological saline serum infiltration)
Description: The placebo intervention will be similar in relation to 2% lidocaine without vasoconstrictor for the skin, but an ultrasound-guided puncture will be performed at the level of the subcutaneous cellular tissue by injecting 3 ml of physiological saline.
Study: NCT04699747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F-18 3F4AP
Description: Subjects will be injected once per imaging session (a maximum of 2 imaging sessions) with up to 10 mCi (±20%) of 18-F 3F4AP as a rapid intravenous bolus (within 1 min).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 3F4AP
Description: Subjects will be injected once per imaging session (a maximum of 2 imaging sessions) with up to 10 mCi (±20%) of 18-F 3F4AP as a rapid intravenous bolus (within 1 min).
Study: NCT06265922

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency repetitive transcranial magnetic stimulation
Description: High frequency repetitive transcranial magnetic stimulation will be applied over mid line of cerebellum using circular coil. Ten repetition rate (frequency) in 40 trains with one intertrain interval will be applied for three times a week for two weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: Sham repetitive transcranial magnetic stimulation will be applied Perpendicular away from the cerebellum using the same circular coil. The same parameters will be used with the same duration also numbers of sessions are the same like the active comparator group to assure the patients blindness
Study: NCT04865523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage
Description: Manual lymphatic drainage is a technique that through gentle passes facilitates the flow of lymph through manual therapy techniques based on Vodder therapy. This technique is being studied to know its effectiveness in pain and for this reason we want to carry out this research.
Study: NCT05870982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early TRE
Description: Participants will be instructed to eat only during an 8-hour window starting 1-2 hours after waking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late TRE
Description: Participants will be instructed to eat only during an 8-hour window starting 5-6 hours after waking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DCR
Description: Participants will be instructed to reduce caloric intake by 25%.
Study: NCT05048550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near vision spectacles
Description: Near vision spectacles prescribed for full time wear (Add+3.00DS to the full cycloplegic refraction). These glasses will be changed to reflect changes in refractive error or frame fit as appropriate at follow up.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near vision spectacles
Description: Near vision spectacles prescribed for full time wear (Add+3.00DS to the full cycloplegic refraction). These glasses will be changed to reflect changes in refractive error or frame fit as appropriate at follow up.
Study: NCT04577157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth usingWhatsApp multifaceted educational and reminder module intervention to improve adherence
Description: This multifaceted educational and reminder module is named Health@click. The content of the reminder module has been made based on The Health Belief Model and self-determination theory.~1. Daily notes for medication reminders,~2. Daily a voice message with the same content will be delivered.~3. Daily Graphics-based Reminder (GBR).~4. Twice-weekly Graphics-based Messages (GBM) according to Health believe model and Self-determination theory constituents.~5. Once-weekly lifestyle advice through video~6. Hypertension at a glance, complete information will be provided(Optional)~7. 24/7 help provision service will be given to the participants. A qualified doctor will be there to provide this educational support. Support will be including the dose of medicine, frequency, mode of action, effects of medicine on current illness, side effects, and interaction with different foods (Optional).
Study: NCT06071728

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572)
Description: Subjects will receive Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572) (3,712mg) or placebo for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572)
Description: Subjects will receive Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572) (3,712mg) or placebo for 12 weeks.
Study: NCT04585503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrode implantation
Description: The intervention consist in implanting 6 electrodes in subdural or intra cortical position and monitor the central nervous system activity. This monitoring will be additional to the usual monitoring.
Study: NCT05903209

Intervention type: DEVICE
Intervention: Chang Gung Pneumothorax Detection Software
Description: The Chang Gung Pneumothorax Detection Software is an independent software as a medical device, which inputs digital Chest X-Ray to automatically detect whether there is a pneumothorax. The inferred results output by this software can assist clinicians or professional medical personnel to identify whether a patient has pneumothorax.~This product is only used to analyze the digitized Chest X-Ray DICOM of patients over 20 years old and under 100 years old.
Study: NCT03090048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Vitamin A 2-3 % concentration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Vitamin A 2-3 % concentration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: azithromycin monohydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: azithromycin monohydrate
Study: NCT05507359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clove gel
Description: 4.7% (Pain Out Dental Gel, Colgate Palmolive India Ltd, Solan, India) clove gel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Benzocaine gel
Description: 20% Benzocaine gel (Opahl gel)
Study: NCT05322044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Financial incentives dependent upon adherence will be given to participants alongside additional EMD associated app features for 12-weeks.
Study: NCT06255678

Intervention type: DIAGNOSTIC_TEST
Intervention: Angiography-based vessel fractional flow reserve (vFFR) calculation
Description: vFFR is calculated from routinely taken angiography images during PCI using a CAAS workstation (Pie Medical Imaging, Maastricht, the Netherlands)
Study: NCT06448416

Intervention type: PROCEDURE
Intervention: UBE
Description: Patients with HDL were treated with UBE
Study: NCT04641338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination Dipyrone and Codeine
Description: Fixed dose combination: dipyrone 1000 mg + codeine 30 mg every 6 hours if necessary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyrone
Description: use of 1000 mg dipyrone every 6 hours if necessary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine
Description: 30 mg codeine every 6 hours if necessary.
Study: NCT05717348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES014
Description: ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES014
Description: ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
Study: NCT05859035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KIOS Informational App
Description: The KIOS informational app will contain a user interface that includes a login page, true/false questions for the user to answer, verified public domain educational information about drug and alcohol use, Likert-type questions regarding the information presented, and a closing Thank You screen.
Study: NCT06007781

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 injections - given on Day 1 and the second given between Day 29 - Day 57

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIL-214
Description: 2 injections - given on Day 1 and the second given between Day 29 - Day 57
Study: NCT05297630

Intervention type: OTHER
Intervention: Evaluation of the evolution of biological markers from the biobank.
Description: The evolution of sST2, copeptin, chromogranin, NGAL, suPAR and cystatin will be evaluated between Day 0 and Month 1